Pfizer’s Ibrance Clears Initial Barrier for UK’s Early Access Scheme
Pfizer’s new cancer drug Ibrance has cleared the initial barrier to joining the UK’s Early Access to Medicines Scheme after
Read more
Clinical Research Society
International Society for Clinical Research and Translational Medicine